• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Fibrinolytic and Antithrombotic Therapy

Fibrinolytic and Antithrombotic Therapy

Theory, Practice, and Management

9780195155648
393,12 zł
353,81 zł Zniżka 39,31 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 353,81 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
Thrombotic disorders of the circulatory system represent the leading cause of morbidity, motality, and health care expenditure in the United States. Fibrinolytic and Antithrombotic Therapy provides a practical, evidence-based approach to the management of thrombotic disorders for all clinicians involved in the care of patients with these disorders. It provides not only vital conceptual information on fibrinolytic and antithrombotic therapy, but also the means to apply it toeveryday decision making and patient care. Focusing on management guidelines and critical pathways, the text stresses practicality and usability. It will be a valuable resource for the wide range of clinicians involved in the care of patients with these disorders, including cardiologists, emergencyphysicians, primary care physicians, haematologists, neurologists, intensivists, pharmacists, and nurse practitioners. The origins of mammalian blood coagulation can be traced back over 400 million years. Despite its long history, it is only within the past century that this complex and pivotal teleologic system has begun to be understood. Most recently, the intricacies of haemostasis and pathologic thrombosis have come to light, leading the way toward new, more effective, and safer treatment modalities. The Second Edition of Fibrinolytic and Antithrombotic Therapy, even more concise and clinically relevant than the First, provides vital, evidence-based information on management of patients with arterial and venous thrombotic disorders. Since the First Edition, the text has been expanded to cover the evolving topics of atherothrombosis, thrombocardiology, haematologic/thrombophilic conditions, and vascular medicine. It includes up-to-date guidelines for antithrombotic and fibrinolytictherapy, and offers concise summaries of current standards of care. Chapters are dedicated to discussions of patient-specific therapeutics and to the importance of genomics, proteomics, and metabolomics in defining genotype-phenotype relationships, while throughout the book coagulation, inflammation, andvascular medicine are newly examined as elements in an intricately-linked triad of biochemical and cellular based phenomenology.
Szczegóły produktu
OUP USA
84849
9780195155648
9780195155648

Opis

Rok wydania
2006
Numer wydania
2
Oprawa
miękka foliowana
Liczba stron
424
Wymiary (mm)
141 x 210
Waga (g)
482
  • Part I: Fundamental Scientific Principles; Historical Perspectives of Haemostasis, Coagulation, and Fibrinolysis: A Foundation for Understanding Thrombotic Disorers and Developing Effective Treatment; Vascular Biology, Thromboresistance and Inflammation; Atherosclerosis and Arterial Thrombosis; Venous Thromboembolism; Cardiac Chamber, Aortic and Valvular Thromboembolism; Part II: Fibrinolytics and Platelet Antagonists; Fibrinolytic Agents; Asprin; Clopidogrel; Platelet Glycoprotein llb/llla Receptor Antagonists; Aggrenox and Cilostazol; Novel Platelet Antagonists; Combination Pharmacotherapy; Facilitated Percutaneous Coronary Interventions; Part III: Anticoagulants; Thrombin-Directed Therapy; Factor Xa Inhibitors; Direct Thrombin Inhibitors; Novel Anticoagulants; Part IV: Management of Arterial Thrombotic Disorders; Acute Coronary Syndromes; Peripheral Vascular Disease and Stroke; Valvular Heart Disease and Atrial Fibrillation; Plaque Stabilizing Therapies; Part V: Management of Venous Thrombotic Disorders; Venous Thromboembolism Prophylaxis; Venous Thromboembolism Treatment; Part VI: Genomics, Proteomics and Suspected Thrombophilias; Fundamentals and Patient Evaluation; Part VII: Monitoring Antithrombotic Therapy; Platelet Antagonists; Anticoagulants; Anticoagulation Clinics and Self-Testing; Part VIII: Complications of Treatment and Their Management; Platelet Antagonists; Anticoagulants; Fibrinolytic Agents; Appendixes; A Antithrombotic and Fibrinolytic Agents; B Drug Dosing with Renal Insufficiency;
Komentarze (0)